Company: RGNX
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0000950170-25-038770
Chunk: 227

Company: REGENXBIO Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1B
Chunk 227
---

    )

    Accumulated deficit

    (932,149
    )

    (705,047
    )

    Total stockholders’ equity

    259,651

    311,742

    Total liabilities and stockholders’ equity
     
    $
    465,989

    $
    573,970

The accompanying notes are an integral part of these consolidated financial statements.

90

REGENXBIO INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except per share data)

    Years Ended December 31,

    2024

    2023

    2022

    Revenues

    License and royalty revenue
     
    $
    83,328

    $
    90,242

    $
    112,724

    Total revenues

    83,328

    90,242

    112,724

    Operating Expenses

    Cost of revenues

    33,567

    37,213

    54,545

    Research and development

    208,522

    232,266

    242,453

    General and administrative

    76,619

    88,494

    85,281

    Credit losses (recoveries)

    (5,000
    )

    —

    —

    Impairment of long-lived assets

    2,101

    —

    —

    Other operating expenses (income)

    865

    397

    (6,679
    )

    Total operating expenses

    316,674

    358,370

    375,600

    Loss from operations

    (233,346
    )

    (268,128
    )

    (262,876
    )

    Other Income (Expense)

    Interest income from licensing

    174

    25

    342

    Investment income

    18,729

    11,319

    5,383

    Interest expense

    (12,659
    )

    (6,862
    )

    (23,254
    )

    Total other income (expense)

    6,244

    4,482

    (17,529
    )

    Loss before income taxes

    (227,102
    )

    (263,646
    )

    (280,405
    )